©2026 Hevantra. All Rights Reserved | Designed by SlashMonk
Services
Services
Evidence Reviews And Synthesis
We conduct methodologically rigorous literature reviews and synthesize existing clinical and economic evidence to establish a robust foundation for product value. Our approaches are tailored to the decision context, supporting comparative effectiveness, economic modelling, and market access decision-making.
Key Services
- Conduct Systematic and Targeted Literature Reviews (SLRs / TLRs) to comprehensively identify clinical efficacy, safety, economic outcomes, cost and resource use and health-related quality-of-life evidence
- Deliver Rapid and Scoping Reviews to support early decision-making and evidence planning
- Perform Meta-Analysis and Network Meta-Analysis (NMAs) to enable robust indirect comparisons across complex treatment networks
- Conduct Indirect Treatment Comparisons (ITC) using Individual Patient Data (IPD), including:
- Matching-Adjusted Indirect Comparisons (MAIC)
- Simulated Treatment Comparisons (STC)
All evidence synthesis activities are conducted in accordance with PRISMA, Cochrane, and ISPOR best-practice guidelines, ensuring transparency, reproducibility, and acceptance by major global HTA and reimbursement bodies.
Health Economic Modelling
We deliver robust, decision-focused economic modelling and advanced analytical solutions to support evidence generation across the entire product life cycle. All modelling approaches are carefully tailored to the specific decision context and developed in line with global payer and HTA expectations.
Key Services
- Develop Cost-Effectiveness Models (CEM) to evaluate clinical and economic value and support reimbursement decisions
- Develop Budget Impact Models (BIM) to assess financial implications for payers and healthcare systems
- Apply Early Economic Models in the initial stages of drug development to identify evidence gaps, strengthen value propositions, and inform market access, payer reimbursement, and investment decisions across the product life cycle
- Perform Model Adaptation by tailoring cost-effectiveness models for new geographies through country-specific input updates to reflect local clinical practice, costs, and HTA requirements
Our models draw on decision-analytic methods, including Markov frameworks and partitioned survival models, ensuring methodological rigor, transparency, and HTA acceptability.
Value Communication And Access
We translate complex clinical and economic evidence into clear, compelling value narratives and decision-support tools that resonate with payers, policymakers, and healthcare providers, supporting pricing, reimbursement, and access outcomes across global markets.
Key Services
- Development of Global Value Dossiers (GVDs) and AMCP dossiers aligned with payer and HTA requirements
- Creation of Payer value decks and Objection-handlers to support payer engagement and access discussions
- Value story development and messaging frameworks to ensure consistent, evidence-based communication of product value
- Scientific writing and publication support, including manuscripts, abstracts, posters, and congress materials